Haemonetics (NYSE:HAE) Price Target Raised to $74.00 at JPMorgan Chase & Co.

by · The Cerbat Gem

Haemonetics (NYSE:HAE – Get Free Report) had its price objective hoisted by research analysts at JPMorgan Chase & Co. from $62.00 to $74.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential downside of 11.05% from the company’s current price.

Several other research analysts also recently commented on HAE. Citigroup lowered their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. Barrington Research boosted their price target on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Raymond James Financial reissued an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research note on Friday, November 14th. BTIG Research reiterated a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a report on Friday, November 21st. Finally, Needham & Company LLC upped their price objective on shares of Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.90.

View Our Latest Stock Report on HAE

Haemonetics Trading Down 1.5%

NYSE:HAE traded down $1.26 on Friday, reaching $83.19. The company’s stock had a trading volume of 536,275 shares, compared to its average volume of 854,914. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The business’s 50-day moving average price is $64.72 and its two-hundred day moving average price is $64.33. The firm has a market cap of $3.89 billion, a PE ratio of 24.29, a PEG ratio of 1.64 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64.

Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm’s revenue was down 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts anticipate that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Institutional investors have recently modified their holdings of the company. Quarry LP increased its stake in Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. GAMMA Investing LLC increased its holdings in shares of Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Haemonetics by 216.4% during the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 567 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its position in Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 837 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About Haemonetics

(Get Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Further Reading